

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216. PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax) PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
- Hand Carry directly to:
 U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name, Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
 - U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202
- 4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office, Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 10/020,436
attn: new rules case:	s: Please disregard english "Alpha" Headers, which were inserted by Pto Software
1Wrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.
3Misaligned Amino Numbering	The numbering under each 5th amino acid is misaligned. Do not use tab codes between numbers; use space characters, instead.
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.
6Patentin 2.0 "bug"	A "bug" in Patentin version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, Patentin would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.
8 Skipped Sequences (NEW RULES)	Sequence(s) missing. If Intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000
9Use of n's or Xsa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa; and which residue n or Xaa represents.
Invalid <213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220><223> section is required when <213> response is Unknown or is Artificial Sequence
11Use of <220>	Sequence(s) missing the <220> "Feature" and associated numeric identifiers and responses. Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)
PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.
3Misuse of n	n can only be used to represent a single nucleotide in a nucleic acid sequence. N is not used to represent any value not specifically a nucleotide.

AMC/MH - Biotechnology Systems Branch - 08/21/2001



DATE: 02/21/2002

OIPE

```
TIME: 11:29:58
                PATENT APPLICATION: US/10/020,436
                Input Set : A:\39200.app
                Output Set: N:\CRF3\02212002\J020436.raw
 3 <110> APPLICANT: PEPTIDE THERAPEUTICS LIMITED et al
 5 <120> TITLE OF INVENTION: A METHOD FOR MAPPING THE ACTIVE SITES BOUND BY ENZYMES
         THAT COVALENTLY MODIFY SUBSTRATE MOLECULES
 8 <130> FILE REFERENCE: 39200A/JMD/NT
10 <140> CURRENT APPLICATION NUMBER: US/10/020,436
11 <141> CURRENT FILING DATE: 2001-12-18
                                                              Does Not Comply
13 <150> PRIOR APPLICATION NUMBER: GB 9722818.3
14 <151> PRIOR FILING DATE: 1997-10-30
                                                          Corrected Diskette Needed
16 <160> NUMBER OF SEQ ID NOS: 21
                                                           pp 1-3
18 <170> SOFTWARE: PatentIn Ver. 2.1
20 <210> SEQ ID NO: 1
21 <211> LENGTH: 3
22 <212> TYPE: PRT
23 <213> ORGANISM: Artificial Sequence
25 <220> FEATURE:
26 <223> OTHER INFORMATION: Description of Artificial Sequence: formula for a
27
         library comprising natural and/or unnatural amino
28
         acid residues or peptidomimetics
30 <220> FEATURE:
31 <221> NAME/KEY: UNSURE
32 <222> LOCATION: (1)
33 <223> OTHER INFORMATION: Xaa at position 1 is any natural or unnatural
                                                      invalid-sel item 5 on
Euro Summary Sheet
         amino acid residue or peptidomimetic and/is
35
       repeated x times
37 <220> FEATURE:
38 <221> NAME/KEY: UNSURE
39 <222> LOCATION: (2)
40 <223> OTHER INFORMATION: Xaa at position 2 is a non-degenerate modifiable
41
         natural or unnatural amino acid residue or
42
         peptidomimetic
44 <220> FEATURE:
45 <221> NAME/KEY: UNSURE
46 <222> LOCATION: (3)
47 <223> OTHER INFORMATION: Xaa at position 3 is any natural or unnatural
48
         amino acid residue or peptidomimetic and is
49
        repeated y times.
51 <220> FEATURE:
52 <221> NAME/KEY: UNSURE
53 <222> LOCATION: (1)..(3)
54 <223> ΩTHER—INFORMATION: x and y are each independently 0 or an integer; (x
55
         (+ y) = (n - 1); and n = an integer from 3 to 8,
56
         preferably 5
```

RAW SEQUENCE LISTING

58 <400> SEQUENCE: 1

DATE: 02/21/2002

TIME: 11:29:58

Input Set : A:\39200.app Output Set: N:\CRF3\02212002\J020436.raw 60 63 <210> SEQ ID NO: 2 64 <211> LENGTH: 3 65 <212> TYPE: PRT 66 <213> ORGANISM: Artificial Sequence 68 <220> FEATURE: 69 <223> OTHER INFORMATION: Description of Artificial Sequence: formula for library used to identify protein kinase inhibitor 70 71 molecules 73 <220> FEATURE: 74 <221> NAME/KEY: UNSURE 75 <222> LOCATION: (1) 76 <223> OTHER INFORMATION: Xaa at position 1 is any natural or unnatural amino acid residue or peptidomimetic and is stem 5 (repeated x times 78 80 <220> FEATURE: 81 <221> NAME/KEY: UNSURE 82 <222> LOCATION: (3) 83 <223> OTHER INFORMATION: Xaa at position 3 is any natural or unnatural amino acid residue or peptidomimetic and is repeated y times 87 <220> FEATURE: 88 <221> NAME/KEY: UNSURE 89 <222> LOCATION: (1)..(3) -90 <223> OTHER INFORMATION: x and y are each independently 0 or an integer; (x 91 '+ y) = (n-1); and n = an integer from 3 to 8, 92 preferably 5 94 <400> SEQUENCE: 2 95/ Xaa Tyr/Xaa 99 <210> SEQ ID NO: 3 100 <211> LENGTH: 8 101 <212> TYPE: PRT 102 <213> ORGANISM: Artificial Sequence 104 <220> FEATURE: 105 <223> OTHER INFORMATION: Description of Artificial Sequence: consensus peptide substrate for ZAP-70 106 108 <220> FEATURE: 109 <221> NAME/KEY: UNSURE 110 <222> LOCATION: (1) 111 <223> OTHER INFORMATION: Biotin-epsilon-aminohexanoic acid is linked to the 112 aspartic acid residue at position 1 114 <220> FEATURE: 115 <221> NAME/KEY: UNSURE 116 <222> LOCATION: (8) 117 <223> OTHER INFORMATION: Leucine at position 8 is Norleucine 119 <400> SEQUENCE: 3 120 Asp Glu Glu Asp Tyr Phe Glu Leu

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/020,436

DATE: 02/21/2002

TIME: 11:29:58

Input Set : A:\39200.app Output Set: N:\CRF3\02212002\J020436.raw 121 124 <210> SEO ID NO: 4 125 <211> LENGTH: 3 126 <212> TYPE: PRT 127 <213> ORGANISM: Artificial Sequence 129 <220> FEATURE: 130 <223> OTHER INFORMATION: Description of Artificial Sequence: general formula for peptide library containing substrates for protein serine or serine/threonine kinase 132 133 enzyme 135 <220> FEATURE: 136 <221> NAME/KEY: UNSURE 137 <222> LOCATION: (1) 138 <223> OTHER INFORMATION: Xaa at position 1 is any natural or unnatural 139 amino acid residue or peptidomimetic and is 140 repeated x times rtem 3 142 <220> FEATURE: 143 <221> NAME/KEY: UNSURE 144 <222> LOCATION: (3) 145 <223> OTHER INFORMATION: Xaa at position 3 is any natural or unnatural amino acid residue or peptidomimetic and is 147 <u> repeated v times</u> 149 <220> FEATURE: item 5 150 <221> NAME/KEY: UNSURE 151 <222> LOCATION: (1)..(3)_ 152 <223> OTHER INFORMATION: x and y are each independently 0 or an integer; (x 153 + y) = (n - 1); and n = an integer from 3 to 8,154 preferably 5 156 **≠40**0> SEQUENCE: 4 -> 157 (Xaa) Sex Xaa 158 161 <210> SEQ ID NO: 5 162 <211> LENGTH: 36 163 <212> TYPE: DNA 164 <213> ORGANISM: Artificial Sequence 166 <220> FEATURE: 167 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer 168 used to amplify the coding sequence for human ZAP-70 amino acids 306-615 from Jurkat T cell cDNA 169 171 <400> SEQUENCE: 5 172 ccgggatccg ccatgcccat ggacacgagc gtgtat 36 174 <210> SEQ ID NO: 6 175 <211> LENGTH: 57 176 <212> TYPE: DNA 177 <213> ORGANISM: Artificial Sequence 179 <220> FEATURE: 180 <223> OTHER INFORMATION: Description of Artificial Sequence: PCR primer 181 used to amplify the coding sequence for human 182 ZAP-70 amino acids 306-615 from Jurkat T cell cDNA

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/020,436

RAW SEQUENCE LISTINGPATENT APPLICATION: **US/10/020,436**DATE: 02/21/2002
TIME: 11:29:58

Input Set : A:\39200.app

Output Set: N:\CRF3\02212002\J020436.raw

184 <400> SEQUENCE: 6 185 gggggateet eagtggtggt ggtggtggtg ggeaeaggea geeteageet tetgtgt 187 <210> SEQ ID NO: 7 188 <211> LENGTH: 5 189 <212> TYPE: PRT 190 <213> ORGANISM: Artificial Sequence 192 <220> FEATURE: 193 <223> OTHER INFORMATION: Description of Artificial Sequence: sequence of 194 phosphorylated motif identified by screen of library peptides 197 <400> SEQUENCE: 7 198 Asp Glu Glu Asp Tyr 199 1 202 <210> SEQ ID NO: 8 203 <211> LENGTH: 5 204 <212> TYPE: PRT 205 <213> ORGANISM: Artificial Sequence 207 <220> FEATURE: 208 <223> OTHER INFORMATION: Description of Artificial Sequence: sequence of 209 phosphorylated motif identified by screen of 210 library peptides 212 <400> SEQUENCE: 8 213 Asp Glu Glu Tyr Phe 214 217 <210> SEQ ID NO: 9 218 <211> LENGTH: 5 219 <212> TYPE: PRT 220 <213> ORGANISM: Artificial Sequence 222 <220> FEATURE: 223 <223> OTHER INFORMATION: Description of Artificial Sequence: sequence of 224 phosphorylated peptide motif identified by screen 225 of library peptides 227 <400> SEQUENCE: 9 228 Asp Glu Tyr Glu Phe 229 1 232 <210> SEQ ID NO: 10 233 <211> LENGTH: 5 234 <212> TYPE: PRT 235 <213> ORGANISM: Artificial Sequence 237 <220> FEATURE: 238 <221> NAME/KEY: UNSURE 239 <222> LOCATION: (5) 240 <223> OTHER INFORMATION: Leucine at position 5 is Norleucine 242 <220> FEATURE: 243 <223> OTHER INFORMATION: Description of Artificial Sequence: sequence of 244 phosphorylated motif identified by screen of 245 library peptides 247 <400> SEQUENCE: 10 248 Asp Tyr Phe Glu Leu

RAW SEQUENCE LISTINGPATENT APPLICATION: US/10/020,436

DATE: 02/21/2002

TIME: 11:29:58

Input Set : A:\39200.app

Output Set: N:\CRF3\02212002\J020436.raw

```
249
      1
252 <210> SEQ ID NO: 11
253 <211> LENGTH: 5
254 <212> TYPE: PRT
255 <213> ORGANISM: Artificial Sequence
257 <220> FEATURE:
258 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide
          identified as a preferred substrate for Syk
261 <400> SEQUENCE: 11
262 Asp Glu Glu Asp Tyr
263
      1
266 <210> SEQ ID NO: 12
267 <211> LENGTH: 5
268 <212> TYPE: PRT
269 <213> ORGANISM: Artificial Sequence
271 <220> FEATURE:
272 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide
          identified as a preferred substrate for Syk
275 <400> SEQUENCE: 12
276 Asp Glu Glu Tyr Asp
277
      1
280 <210> SEQ ID NO: 13
281 <211> LENGTH: 5
282 <212> TYPE: PRT
283 <213> ORGANISM: Artificial Sequence
285 <220> FEATURE:
286 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide
287
          identified as a preferred substrate for Syk
289 <400> SEQUENCE: 13
290 Asp Glu Tyr Glu Asp
     1
294 <210> SEQ ID NO: 14
295 <211> LENGTH: 5
296 <212> TYPE: PRT
297 <213> ORGANISM: Artificial Sequence
299 <220> FEATURE:
300 <223> OTHER INFORMATION: Description of Artificial Sequence: peptide
          identified as a preferred substrate for Syk
303 <400> SEQUENCE: 14
304 Asp Tyr Glu Glu Val
305
     1
308 <210> SEQ ID NO: 15
309 <211> LENGTH: 5
310 <212> TYPE: PRT
311 <213> ORGANISM: Artificial Sequence
313 <220> FEATURE:
314 <221> NAME/KEY: UNSURE
315 <222> LOCATION: (5)
316 <223> OTHER INFORMATION: Leucine at position 5 is Norleucine
```

VERIFICATION SUMMARY

DATE: 02/21/2002

PATENT APPLICATION: US/10/020,436

TIME: 11:29:59

Input Set : A:\39200.app

Output Set: N:\CRF3\02212002\J020436.raw

L:10 M:270 C: Current Application Number differs, Replaced Current Application Number

L:11 M:271 C: Current Filing Date differs, Replaced Current Filing Date

L:59 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1 L:95 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:2 L:157 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:4